Nutraferon MYTRANS-S 360 TAB

While 360 mg of Mycophenolate Sodium delivers the same active amount of mycophenolic acid as 500 mg of MMF, the enteric-coated delayed-release matrix bypasses the stomach and dissolves in the neutral pH of the small intestine, reducing upper GI side effects and helping prevent transplant dose reductions.

No. Delayed-release Mycophenolate Sodium (360 mg) and immediate-release Mycophenolate Mofetil (500 mg) have different release profiles and must never be switched without explicit prescribing physician instructions.

Complete Blood Counts (CBC with differential) are checked weekly during the first month, twice monthly during months 2 and 3, and monthly thereafter through the first year to monitor for neutropenia, leukopenia, or pure red cell aplasia, alongside renal and liver panels.

Boxed Teratogenicity Warning: Mycophenolate causes a high rate of first-trimester miscarriage and severe congenital malformations. Female patients of childbearing potential must have two negative pregnancy tests before starting and use effective contraception before, during, and for 6 weeks after stopping therapy. Sexually active male patients (or their female partners) must use reliable contraception during and for 90 days after stopping therapy. Patients must not donate blood during therapy or for 6 weeks after stopping, and men must not donate semen during therapy or for 90 days after stopping.

Separate by at least 2 hours from magnesium/aluminum antacids, iron, calcium, and Sevelamer (`SVEECAR TAB`), which reduce MPA absorption. Avoid Cholestyramine and Rifampin (which block enterohepatic recirculation), and monitor closely with Acyclovir/Valacyclovir/Ganciclovir (compete for renal tubular secretion) and Azathioprine (never co-administer due to severe bone marrow suppression).